ELEMENT-SIX
21.9.2021 01:03:08 CEST | Business Wire | Press release
Element Six, part of the De Beers Group, has launched DNV-B14™, its newest general-purpose chemical vapour deposition (CVD) quantum-grade diamond, an ideal material for quantum technologies such as magnetic field devices, RF sensors, solid-state gyroscopes and room temperature masers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005612/en/
The latest solution in Element Six’s DNV™ Series, DNV-B14™ expands the company’s range of advanced materials for emerging quantum technologies. Diamond containing nitrogen-vacancy (NV) centres offers researchers a unique solid-state platform with spin qubits that can be initialised and read out at room temperature, with long qubit lifetimes. These properties stem from diamond’s unique structure and strong bonds.
DNV-B14™ is designed to provide the end-user with a uniform and high density of NV spin centres - more than a 10-fold increase in NV density compared to DNV-B1™, the first material in the DNV™ Series. Launched last year, DNV-B1™ was winner of the SPIE Prism Award in the Quantum category in March 2021.
The combination of its engineered properties makes DNV-B14™ an ideal solution for experimentation and development of a range of technologies, such as ensemble NV-based vector magnetometry and room-temperature masers.
Dr Daniel Twitchen, Chief Technologist, commented, “Element Six’s founder, Sir Ernest Oppenheimer said no great industry can exist or develop without fundamental research. The DNV™ Series represents exactly that, with sustained R&D within our CVD team spanning over ten years and working across an eco-system that includes large companies, start-ups and some of the world’s leading Universities”.
Element Six diamond with NV densities comparable to DNV-B14™ has already been utilised in the development of high-sensitivity fibre-coupled magnetometers . Without the need for cumbersome cooling equipment, such devices can be made compact, and even portable. They are the ideal enabler of medical diagnostic techniques such as magnetocardiography (MCG) and magnetoencephalography (MEG).
Element Six’s engineered diamond research has also accelerated the delivery of many other breakthroughs in quantum research, including in 2018, when Imperial College London utilised engineered single crystal material in the development of the world’s first continuous-wave, room-temperature, solid-state maser (the microwave equivalent of a laser). Lockheed Martin’s 2019 Dark Ice program also relies on a DNV-enabled magnetometer that measures the direction and strength of nearly imperceptible magnetic field anomalies, opening up new possibilities in GPS-denied navigation.
- ENDS -
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005612/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
